GSK-2636771
GSK-2636771 is an inhibitor of the p110β isoform of PI3K. GSK-2636771 displays anticancer chemotherapeutic activity in PTEN-deficient cancers such as glioblastomas, prostate cancers, and endometrial cancers. This compound is currently in clinical trials.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18929502
| Cas No. |
1372540-25-4 |
|---|---|
| Purity |
≥98.5% |
| Formula |
C22H22F3N3O3 |
| Formula Wt. |
433.42 |
| IUPAC Name |
2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid |
| Solubility |
Soluble in DMSO, and water with 1 eq. of base |
| Appearance |
White Powder |
Weigelt B, Warne PH, Lambros MB, et al. PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clin Cancer Res. 2013 Jul 1;19(13):3533-44. PMID: 23674493.
